PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects
Alaaeldin Fayez, Nora N. Esmaiel, Haiam Abdel Raouf, Mohamad M. Aboelenin, Riham M. Aly, Ghada Nour Eldeen · 2026
Read PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects by Alaaeldin Fayez, Nora N. Esmaiel, Haiam Abdel Raouf, Mohamad M. Aboelenin, Riham M. Aly, Ghada Nour Eldeen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427650.txt.
Description
Alaaeldin Fayez and colleagues test, in a 2026 lab study, a compound meant to correct a faulty signal in developing heart cells. Conotruncal defects, malformations of the heart's outflow region, make up about a third of birth heart defects. A fatty signal molecule called PIP3 is thought to run too high in these conditions. The team grew heart-like cells from human fat stem cells to model the problem.
After 21 days the grown cells showed the striped look of heart muscle and raised two heart gene markers. Adding PIP3 and then the test compound changed measured PIP3 levels sharply, in line with the blocker binding its partner protein. Cell work alone cannot show patient benefit. Still, the result gives a first candidate regulator for a defect group that lacks drug options.
Catalog record
| CREATOR | Alaaeldin Fayez, Nora N. Esmaiel, Haiam Abdel Raouf, Mohamad M. Aboelenin, Riham M. Aly, Ghada Nour Eldeen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |